Sustaining the Legacy of the Massachusetts Life Sciences Cluster
Excerpt from the Article:
In June, MassBio released its State of Possible 2025 report, a five-year strategic plan for Massachusetts and MassBio to ensure the life sciences cluster’s long-term success. To learn more about how this report will serve as a roadmap for the next five years and beyond, we sat down with MassBio’s new Board Chair, and CEO & President of Unum Therapeutics, Chuck Wilson.
MassBio’s State of Possible 2025 Report identified four key opportunities for the Massachusetts life sciences industry to achieve balanced growth in the coming years. Which opportunity (or two) do you believe you can make the greatest impact on during your time as chair?
We must focus on the opportunities that will best support our sustainability. To get there our efforts should be concentrated on the growth of commercialization and manufacturing of therapies here in Massachusetts, and the expansion of the cluster beyond Cambridge/Boston. Our strength in R&D has cultivated an ecosystem of innovation that is the envy of the world and led to improved outcomes for patients. Similarly, the life sciences industry is highly concentrated in Kendall Square. In both cases, without growth it’s hard to envision a truly sustainable ecosystem.
Click the button below to read the Article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?